Literature DB >> 11590490

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11590490     DOI： 10.1310/hct.2000.1.1.008

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN： 1528-4336


× No keyword cloud information.
  102 in total

1.  Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries.

Authors:  R W Shafer; D R Jung; B J Betts
Journal:  Nat Med       Date:  2000-11       Impact factor: 53.440

2.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

3.  The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.

Authors:  P Cinque; C Pierotti; M G Viganò; A Bestetti; C Fausti; D Bertelli; A Lazzarin
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

4.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

5.  Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.

Authors:  Thomas P Giordano; Glenn Bartsch; Yafeng Zhang; Ellen Tedaldi; Judith Absalon; Sharon Mannheimer; Avis Thomas; Rodger D MacArthur
Journal:  AIDS Patient Care STDS       Date:  2010-05       Impact factor: 5.078

6.  Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.

Authors:  Bethany L Morris; Callie A Scott; Timothy J Wilkin; Paul E Sax; Roy M Gulick; Kenneth A Freedberg; Bruce R Schackman
Journal:  HIV Clin Trials       Date:  2012 Jan-Feb

7.  HIV infection and women's sexual functioning.

Authors:  Tracey E Wilson; Girardin Jean-Louis; Rebecca Schwartz; Elizabeth T Golub; Mardge H Cohen; Pauline Maki; Ruth Greenblatt; L Stewart Massad; Esther Robison; Lakshmi Goparaju; Stacy Lindau
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

8.  Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.

Authors:  Steve A Castillo; Jaime E Hernandez; Cindy H Brothers
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

9.  Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.

Authors:  Shehnaz K Hussain; Nancy A Hessol; Alexandra M Levine; Elizabeth Crabb Breen; Kathryn Anastos; Mardge Cohen; Gypsyamber D'Souza; Deborah R Gustafson; Sylvia Silver; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

10.  Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk.

Authors:  Shehnaz K Hussain; Weiming Zhu; Shen-Chih Chang; Elizabeth Crabb Breen; Elena Vendrame; Larry Magpantay; Dan Widney; Daniel Conn; Mary Sehl; Lisa P Jacobson; Jay H Bream; Steven Wolinsky; Charles R Rinaldo; Richard F Ambinder; Roger Detels; Zuo-Feng Zhang; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-18       Impact factor: 4.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.